Subject(s)
Antineoplastic Agents/therapeutic use , Lymphoma/drug therapy , Chlorambucil/therapeutic use , Cyclophosphamide/therapeutic use , Drug Therapy, Combination , Female , Humans , Lymphoma/pathology , Male , Methotrexate/therapeutic use , Middle Aged , Neoplasm Staging , Prednisolone/therapeutic use , Prognosis , Prospective Studies , Random Allocation , VincristineSubject(s)
Lymphoma/therapy , Female , Humans , Lymphoma/diagnosis , Lymphoma/drug therapy , Lymphoma/radiotherapy , Male , Neoplasm Staging , Prospective StudiesABSTRACT
In short form a survey is given concerning the division of the malignant non-Hodgkin-lymphoma according to the classification of Kiel. The subdivision in stages and a proposal for a comprehensive clinical and laboratory investigation programme complete the compilation concerning the diagnostics of the malignant non-Hodgkin-lymphomas.
Subject(s)
Lymphoma/classification , Neoplasm Staging/methods , Humans , Leukemia, Lymphoid/diagnosis , Lymphoma/diagnosis , PrognosisABSTRACT
Up to now the results of the therapy of malignant non-Hodgkin lymphomas are not satisfactory. In order to improve these results decisively it is necessary to develop and to test therapeutic strategies on standardised diagnostic basis. On the basis of the histological classification after Kiel of the malignant non-Hodgkin lymphomas and the clinical stage subdivision of the lympho-granulomatosis after Rye (for the malignant non-Hodgkin lymphomas modified by Musshoff) in the present paper therapeutic recommendations are given which are based on proved therapeutic regimes.
Subject(s)
Lymphoma/therapy , Brain Neoplasms/drug therapy , Brain Neoplasms/radiotherapy , Brain Neoplasms/secondary , Chlorambucil/therapeutic use , Cyclophosphamide/therapeutic use , Humans , Injections, Spinal , Lymphoma/drug therapy , Lymphoma/radiotherapy , Methotrexate/administration & dosage , Methotrexate/therapeutic use , Neoplasm Staging , Prednisolone/therapeutic use , Prognosis , Remission, Spontaneous , Vincristine/therapeutic useSubject(s)
Antibodies, Antinuclear/analysis , Arthritis, Rheumatoid/immunology , Adolescent , Adult , Aged , Female , Humans , Male , Middle AgedABSTRACT
After a short review concerning the side-effect of busulfan (myleran) a case of a myleran lung in a 45-year-old male patient is described who received altogether 408.0 mg myleran, as he suffered from a chronic myeloic leucosis; the special literature is cited and the developmental mechanisms are discussed.